Minerva Neurosciences : Corporate Presentation at LifeSci Partners Corporate Access Event

Corporate Presentation

January 2022

Forward-Looking Statement Safe-Harbor

Forward-Looking Safe Harbor Statement

This presentation contains forward-looking statements. Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of this presentation, and involve certain risks and uncertainties. Forward-looking statements include, but are not limited to, statements herein with respect to the timing and scope of clinical trials and regulatory review and results and outcomes of such clinical trials and regulatory review with roluperidone (MIN-101); the clinical and therapeutic potential of this compound; the likelihood of successful clinical trials, regulatory review, commercialization, and future sales of and potential royalty stream from seltorexant; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies, including the U.S. Food and Drug Administration; our ability to successfully develop and commercialize our therapeutic products; the sufficiency of our current cash position to fund our operations; and management's ability to successfully achieve its goals. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether roluperidone will advance further in the clinical trials process and whether and when, if at all, it will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether any of our therapeutic products or seltorexant will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will be successful; management's ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; changes in expected or existing competition; unexpected litigation or other disputes; the impacts of the COVID-19 pandemic on our business; and general economic conditions. These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption "Risk Factors" in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the Securities and Exchange Commission on November 8th, 2021. Copies of reports filed with the SEC are posted on our website at www.minervaneurosciences.com. The forward-looking statements in this presentation are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.

5th January 2022

2

Minerva Neurosciences (NASDAQ: NERV)

• Founded in 2014
• Our goal is to transform the lives of patients suffering from CNS disease including schizophrenia, depression, insomnia and
  Parkinson's disease.
• Roluperidone is our lead program for the treatment of negative symptoms in patients diagnosed with schizophrenia.

3

Roluperidone

Treatment of negative symptoms in patients diagnosed with schizophrenia

4

Physicians Cite Negative Symptoms as One of the Key Unmet Needs in Schizophrenia

Treatment targeting negative symptoms (social withdrawal, lack of motivation, reduction in spontaneous speech)

Improved tolerability of drug treatment

Improved options for patients with refractory positive symptoms

Treatments targeting the cognitive deficits in schizophrenia

Treatments addressing noncompliance

Greater understanding of schizophrenia etiology

							7.6			Improvements with
										roluperidone observed
							7.5			in these needs
							7.2
							7.2
							7.1
						6.4
0	1	2	3	4	5	6	7	8	9	10

Mean ranking of each unmet need (1-10)*

*Higher scores denote greater importance assigned to the unmet need. Source: Datamonitor Healthcare's proprietary schizophrenia survey, September 2017

5